New goBalto Activate may accelerate clinical trial startup
goBalto, a San Francisco-based provider of cloud-based clinical study startup solutions, has launched its latest version of goBalto Activate. The third major release of 2015 offers new features that further accelerate clinical study startup.
“Expedited programs, such as 21st Century Cures Act, compassionate use and Right to Try laws, and the recent calls for greater transparency in clinical trial results are a manifestation of the public’s dissatisfaction with the clinical trials process, which has been slow to adopt new innovative technologies, technologies which have the ability to significantly reduce cycle times and get much-needed therapies to those in need faster,” said Sujay Jadhav, goBalto’s CEO.
Jeff Kasher, formerly vice president of clinical innovation and implementation at Eli Lilly, and now president of Patients Can’t Wait and advisor to goBalto, said, “Patients across the globe are waiting for new therapies, but complicated study protocols, globalization and paper-based methods of conducting trials continue to delay market entry. Current thinking looks to an improved study startup process as holding great promise for accelerating clinical trials.”
Activate customers report improved business performance and a reduction in cycle times by 30-plus percent. With more than 2,000 pharmaceutical and CRO users in more than 60 countries using Activate to manage, track and complete study startup tasks, goBalto has the largest industry-proven set of country workflows. Standard “out-of-the-box” country specific regulatory business process workflows allow quick site activation, leading to greater cost savings and faster market entry, making valuable therapies available to patients sooner.